Non-ergot dopamine agonists do not increase the risk of heart failure in patients with Parkinson´s disease

This study investigated whether non-ergot dopamine agonists (DA) are associated with heart failure. Researchers suggested that DA therapy is not related to heart disease.

Levodopa is a main treatment option for Parkinson’s disease. Long-term use of levodopa, however, can lead to motor complications.

Ergot and non-ergot DAs may be used in addition to levodopa. They are associated with lower risks of motor complications but are not as effective as levodopa. Some studies have suggested, however, that non-ergot DAs may be associated with a risk of heart failure. There have been conflicting results, therefore, the relationship between non-ergot DAs and heart disease is still under investigation.

This study reviewed 27 other studies which included patients treated with non-ergot DAs or levodopa alone.

Patients who underwent treatment with non-ergot DAs did not have an increase in the risk of heart failure or any other cardiovascular event (such as heart attack or stroke).

This study determined that non-ergot DAs are not associated with an increased risk of heart failure in patients with Parkinson´s disease.